Genenta Advances Transformation into Saentra Forge, Strengthens ATC Governance and Expands Strategic Industrial Consolidation Platform

Nature Medicine Accepts Manuscript Highlighting Clinical Results from the Company’s Glioblastoma TrialMILAN, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA) in transformation to Saentra Forge (Nasdaq: SAEN), a strategic industrial consolidator focused on biotech, defense, aerospace, and national-security-related technologies, today announced the appointment of Paolo Salvato to the Board of Directors of ATC, a manufacturer of tactical defense systems representing the Company’s initial ...